Head-To-Head Comparison: Femasys (NASDAQ:FEMY) versus Biostage (OTCMKTS:BSTG)

Femasys (NASDAQ:FEMY) and Biostage (OTCMKTS:BSTG) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability and risk.

Profitability

This table compares Femasys and Biostage’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Femasys	-1,757.16%	-119.97%	-76.52%
Biostage	N/A	N/A	-174.43%

Analyst Ratings

This is a breakdown of current recommendations for Femasys and Biostage, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Femasys	0	0	3	0	3.00
Biostage	0	0	0	0	N/A

Femasys presently has a consensus price target of $10.67, suggesting a potential upside of 811.68%. Given Femasys’ higher possible upside, research analysts plainly believe Femasys is more favorable than Biostage.

Earnings & Valuation

This table compares Femasys and Biostage”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Femasys	$950,096.00	27.36	-$14.25 million	($0.84)	-1.39
Biostage	N/A	N/A	-$6.07 million	($0.58)	-7.67

Biostage has lower revenue, but higher earnings than Femasys. Biostage is trading at a lower price-to-earnings ratio than Femasys, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

65.3% of Femasys shares are owned by institutional investors. 12.3% of Femasys shares are owned by insiders. Comparatively, 15.3% of Biostage shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Risk and Volatility

Femasys has a beta of -2.82, indicating that its stock price is 382% less volatile than the S&P 500. Comparatively, Biostage has a beta of -1.02, indicating that its stock price is 202% less volatile than the S&P 500.

About Femasys

Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. The company offers its products to reproductive endocrinologists for infertility products, obstetrics-gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.

About Biostage

Biostage, Inc., a biotechnology company, offers products to cure patients of cancers, injuries, and birth defects of the gastro-intestinal tract and the airways. The company's pipeline includes organ-regeneration technology for the repair or replacement of diseased or damaged organs, as well as product candidates to treat cancer, injury, and birth defects of the bronchus. Its lead product candidate is Biostage Esophageal Implant for the treatment of severe esophageal disease. The company was formerly known as Harvard Apparatus Regenerative Technology, Inc. and changed its name to Biostage, Inc. in March 2016. Biostage, Inc. was founded in 2009 and is headquartered in Holliston, Massachusetts.